Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

27. februar 2017 opdateret af: University of North Carolina, Chapel Hill
This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. An Audio Computer- Assisted Self-Interview (ACASI) at study entry will assess demographic and psychosocial variables of study subjects. Data will also be collected to assess clinic level variables. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. Behavioral data will be collected via ACASI at study entry to assess demographic and psychosocial variables of study subjects. All other data (biomedical, ART, healthcare utilization) at subsequent study visits will be collected via medical record abstraction. Information about missed visits as well as other healthcare utilization data can be abstracted from electronic appointment systems or other electronic systems at the clinical sites. Subject data will be abstracted from medical records for up to a maximum 26 weeks prior to the baseline study visit, as well as up to a maximum 78 weeks after the baseline study visit or through January 31, 2017, whichever occurs first, for a total maximum of 104 weeks or two years per subject. Data will also be collected from each Adolescent Medicine Trials Unit to assess clinic level variables at baseline (within 30 days of protocol registration) and 48 and 96 weeks after baseline. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

924

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Aurora, California, Forenede Stater, 80045
        • University of Colorado/The Children's Hospital
      • Los Angeles, California, Forenede Stater, 90027
        • Children's Hopsital of Los Angeles
    • District of Columbia
      • Washington, District of Columbia, Forenede Stater, 20010
        • Children's Hospital National Medical Center
    • Florida
      • Miami, Florida, Forenede Stater, 33101
        • University of Miami School of Medicine
      • Tampa, Florida, Forenede Stater, 33606
        • University of South Florida
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Stroger Hospital of Cook County
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70112
        • Tulane University Health Sciences Center
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02215
        • Fenway Institute
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48201
        • Children's Hospital of Michigan
    • New York
      • Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Forenede Stater, 38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Baylor College of Medicine/Texas Children's Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

13 år til 24 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

  1. Behaviorally-infected, HIV-positive adolescents and young adults who are currently receiving or plan to receive their medical care at any clinical site that is part of the AMTU;
  2. Ages 13 through 24, inclusive, at the Baseline visit;
  3. Males and females;
  4. Ability to understand spoken English; and
  5. Ability for the AMTU staff to access the subject's medical records for a maximum of 78 weeks after enrollment or through February 2017, whichever occurs first.

Beskrivelse

Inclusion Criteria:

  • Laboratory evidence of HIV-1 infection per Centers for Disease Control and Prevention (CDC) Surveillance Case Definition for HIV Infection, 2014 (Section 1.1) http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm;
  • Behaviorally-acquired HIV after age 9 years;
  • Age 13 through 24 years, inclusive, at the baseline visit (Enrollment);
  • Planning to receive HIV medical care at an AMTU or at any clinical site that is part of the AMTU for the duration of study follow-up

    • If transition to an adult health care provider must occur during the course of study participation, continued AMTU staff accessibility to medical and appointment records;

  • Ability for the AMTU staff to access medical and appointment records for a maximum of 78 weeks after enrollment or through February 2017, whichever occurs first;
  • Ability to understand spoken English;
  • Willing and able to provide signed informed consent or assent;

NOTE: If consent/assent is obtained > 4 weeks prior to the enrollment date, reaffirmation of consent must be obtained prior to starting the Baseline visit.

-Parent or Legal Guardian permission, if applicable; and

In addition to all the criteria listed above, to be considered eligible for enrollment after August 31, 2015, an individual must also meet the following criterion.

-Must be considered either: (a) newly engaged in HIV medical care defined as no previous initial comprehensive HIV medical care visit with consent occurring before, at the time of, or within four weeks following that initial comprehensive visit; or (b) newly re-engaged in HIV medical care defined as attending the last medical appointment more than 52 weeks ago.

*NOTE: The initial HIV medical care appointment is defined as a routine HIV medical appointment where the adolescent attends with a medical provider authorized to prescribe medication.

This HIV medical appointment must be a non-emergency, routine condition-focused exam AND one or more of the following:

  • CD4, VL lab draw and/or review of these lab results;
  • Discussion around HIV ART options;
  • Primary and/or secondary HIV prevention education and counseling; or
  • Diagnosis and treatment of complications of HIV, and of AIDS-defining conditions.

Exclusion Criteria:

  • Presence of serious psychiatric symptoms (e.g., active hallucinations, thought disorder) that would impair the individual's ability to provide true informed consent or participate in the baseline ACASI*;
  • Visibly distraught (e.g., suicidal, homicidal, exhibiting violent behavior) at the time of consent or the baseline ACASI*; or
  • Intoxicated or under the influence of alcohol or other substances at the time of consent or the baseline ACASI*

    • NOTE: If consent/assent is obtained prior to the enrollment date, assessment for these exclusion criteria must be performed again prior to administration of the baseline ACASI (Enrollment). If any are present, the subject cannot be enrolled; do not administer the ACASI. Reassessment of eligibility and enrollment may take place at a later date per the discretion of the treating clinician.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
The proportion of subjects engaged in care at Baseline, per subject year, as defined by the HRSA HAB measure
Tidsramme: Baseline
Baseline
The proportion of subjects engaged in care at Week 26, per subject year, as defined by the HRSA HAB measure
Tidsramme: Week 26
Week 26
The proportion of subjects engaged in care at Week 52, per subject year, as defined by the HRSA HAB measure
Tidsramme: Week 52
Week 52
The proportion of subjects engaged in care at Week 78, per subject year, as defined by the HRSA HAB measure
Tidsramme: Week 78
Week 78
The proportion of subjects engaged in care at Baseline, per subject year, as defined by the DHHS measure
Tidsramme: Baseline
Baseline
The proportion of subjects engaged in care at Week 26, per subject year, as defined by the DHHS measure
Tidsramme: Week 26
Week 26
The proportion of subjects engaged in care at Week 52, per subject year, as defined by the DHHS measure
Tidsramme: Week 52
Week 52
The proportion of subjects engaged in care at Week 78, per subject year, as defined by the DHHS measure
Tidsramme: Week 78
Week 78
The proportion of subjects prescribed antiretroviral therapy at Baseline per subject year
Tidsramme: Baseline
Baseline
The proportion of subjects prescribed antiretroviral therapy at Week 26 per subject year
Tidsramme: Week 26
Week 26
The proportion of subjects prescribed antiretroviral therapy at Week 52 per subject year
Tidsramme: Week 52
Week 52
The proportion of subjects prescribed antiretroviral therapy at Week 78 per subject year
Tidsramme: Week 78
Week 78
The proportion of subjects that have achieved viral suppression at Baseline per subject year
Tidsramme: Baseline
Baseline
The proportion of subjects that have achieved viral suppression at Week 26 per subject year
Tidsramme: Week 26
Week 26
The proportion of subjects that have achieved viral suppression at Week 52 per subject year
Tidsramme: Week 52
Week 52
The proportion of subjects that have achieved viral suppression at Week 78 per subject year
Tidsramme: Week 78
Week 78

Sekundære resultatmål

Resultatmål
Tidsramme
The proportion of subjects with advanced HIV disease at time of first clinical visit defined as a CD4 count < 200 cells/mm3
Tidsramme: Baseline
Baseline
The incidence of STIs in the study population as an indicator of transmission risk at Baseline
Tidsramme: Baseline
Baseline
The incidence of STIs in the study population as an indicator of transmission risk at Week 26
Tidsramme: Week 26
Week 26
The incidence of STIs in the study population as an indicator of transmission risk at Week 52
Tidsramme: Week 52
Week 52
The incidence of STIs in the study population as an indicator of transmission risk at Week 78
Tidsramme: Week 78
Week 78
Number of subjects with mental health issues at Baseline
Tidsramme: Baseline
Baseline
Number of subjects engaging in substance use at Baseline
Tidsramme: Baseline
Baseline
Number of subjects engaging in sexual risk behaviors at Baseline
Tidsramme: Baseline
Baseline
ART adherence rate at Baseline
Tidsramme: Baseline
Baseline
Frequency of missed clinic visits at Baseline
Tidsramme: Baseline
Baseline
Frequency of missed clinic visits at Week 26
Tidsramme: Week 26
Week 26
Frequency of missed clinic visits at Week 52
Tidsramme: Week 52
Week 52
Frequency of missed clinic visits at Week 78
Tidsramme: Week 78
Week 78
Types of services available at each AMTU at Baseline
Tidsramme: Baseline
Baseline
Types of services available at each AMTU at 48 weeks after Baseline
Tidsramme: Week 48
Week 48
Types of services available at each AMTU at 96 weeks after Baseline
Tidsramme: Week 96
Week 96
Proportion of subjects notifying their sexual partners after learning their HIV status
Tidsramme: Baseline
Baseline
Timing of subjects notifying their partners after learning about their HIV status
Tidsramme: Baseline
Baseline
Proportion of subjects with whom partner notification was discussed
Tidsramme: Baseline
Baseline

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Bret Rudy, MD, NYU Langone Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. marts 2015

Primær færdiggørelse (Faktiske)

1. februar 2016

Studieafslutning (Faktiske)

1. februar 2016

Datoer for studieregistrering

Først indsendt

2. april 2015

Først indsendt, der opfyldte QC-kriterier

5. maj 2015

Først opslået (Skøn)

8. maj 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. februar 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. februar 2017

Sidst verificeret

1. marts 2016

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • ATN 125

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV

3
Abonner